Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.

Hill BT, Roberts ZJ, Xue A, Rossi JM, Smith MR.

Bone Marrow Transplant. 2019 Aug 30. doi: 10.1038/s41409-019-0657-3. [Epub ahead of print] No abstract available.

PMID:
31471571
2.

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.

Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, Chawla S, Reichardt P, O'Neal M, Feng A, Jacobs I, Roberts ZJ, Braun A, Bach BA.

World J Surg Oncol. 2018 Sep 19;16(1):191. doi: 10.1186/s12957-018-1478-3.

3.

Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.

Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A.

Leuk Lymphoma. 2018 Aug;59(8):1785-1796. doi: 10.1080/10428194.2017.1387905. Epub 2017 Oct 23. Review.

PMID:
29058502
4.

Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.

Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA.

Ann Surg Oncol. 2015 Sep;22(9):2860-8. doi: 10.1245/s10434-015-4634-9. Epub 2015 Jun 2.

5.

The UNC-6/Netrin receptors UNC-40/DCC and UNC-5 inhibit growth cone filopodial protrusion via UNC-73/Trio, Rac-like GTPases and UNC-33/CRMP.

Norris AD, Sundararajan L, Morgan DE, Roberts ZJ, Lundquist EA.

Development. 2014 Nov;141(22):4395-405. doi: 10.1242/dev.110437.

6.

Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists.

Polumuri SK, Jayakar GG, Shirey KA, Roberts ZJ, Perkins DJ, Pitha PM, Vogel SN.

J Immunol. 2012 Jul 1;189(1):50-60. doi: 10.4049/jimmunol.1003554. Epub 2012 May 25.

7.

The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.

Shirey KA, Nhu QM, Yim KC, Roberts ZJ, Teijaro JR, Farber DL, Blanco JC, Vogel SN.

J Leukoc Biol. 2011 Mar;89(3):351-7. doi: 10.1189/jlb.0410216. Epub 2010 Nov 17.

8.

Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways.

Cole LE, Santiago A, Barry E, Kang TJ, Shirey KA, Roberts ZJ, Elkins KL, Cross AS, Vogel SN.

J Immunol. 2008 May 15;180(10):6885-91.

9.

IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Roberts ZJ, Ching LM, Vogel SN.

J Interferon Cytokine Res. 2008 Mar;28(3):133-9. doi: 10.1089/jir.2007.0992.

PMID:
18338946
10.

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.

Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T, Akira S, Savan R, van Echo D, Fitzgerald KA, Young HA, Ching LM, Vogel SN.

J Exp Med. 2007 Jul 9;204(7):1559-69. Epub 2007 Jun 11.

11.

Murine antibody response to intranasally administered enterotoxigenic Escherichia coli colonization factor CS6.

de Lorimier AJ, Byrd W, Hall ER, Vaughan WM, Tang D, Roberts ZJ, McQueen CE, Cassels FJ.

Vaccine. 2003 Jun 2;21(19-20):2548-55.

PMID:
12744890
12.

Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Güereña-Burgueño F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova GV, Alving CR, Glenn GM.

Infect Immun. 2002 Apr;70(4):1874-80.

Supplemental Content

Loading ...
Support Center